Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD vs BTD for Initial Treatment of Primary Systemic Amyloidosis
ChiCTR-IPR-16008422Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bortezomib, cyclophosphamide, thalidomide and dexamethasone in light-chain amyloidosis (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: complete remission. Started May 2016; status: recruiting.
02
Drugs
bortezomibcyclophosphamidethalidomidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ChiCTR-IPR-16008422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008422.